Arterion

Arterion’s technology is based on microbial-derived cellulose, a unique material that, by controlling the life conditions of the bacteria Acetobacter xylinum, can be used to manufacture implantable and biocompatible biomaterials of any shape and size. As a first clinical application area, Arterion develops artificial vascular grafts, and a performed in vivo evaluation in sheep has shown a patency period of at least thirteen months.

Solution

Artificial Blood Vessels

The first product will be a pure cellulose vessel, which is to be usedas vascular replacement in patients with circulatory problems. All  early verification studies indicate that our cellulose product will have leverage to all known competitors. Arterion is, however, already  performing studies where the inner side of the vessel is coated with molecules selectedfrom a number of possible candidates. Thus two additional patents have been exclusively licensed to the company. The vessels are currently manufactured with an internal diameter between 1.5 and 6 mm and with a length up to 17 cm. However, the manufacturing procedure does not limit the production of thinner, wider, or longer vessels.

Arterion Stories

2010

Apr
20
The Nordic Life Science Review 2010 Q1 includes four pages about the Encubator portfolio company from GIBBS, Arterion as well as a short piece about the Encubator portfolio company from CSE, Denator, signing distribution agreements with Bucher Biotec AG for the Swiss market.
Feb
25
The idea provider for Arterion will be featured in the program Vetenskapens Värld on SVT2 on Monday, March 1st at 20:00.
Feb
12
Arterion has been rewarded the MedTech Investment Day Award for 2010 for having the highest potential to become an expanding international company.

2009

Dec
3
Opportunity to perform diploma work at Arterion is available during spring of 2010.
Sep
14
Arterion AB develops small diameter artificial blood vessels to be used as replacement grafts in humans. By using microbial-derived cellulose and controlling the habitat of the microbes Arterion can create vessels with better mechanical and biological properties than all known competitors.
May
1
Arterion welcomes the new Production Manager Kristoffer Drotz. Kristoffer's already has a deep insight and knowledge in bacterial cellulose and his earlier work includes e.g. Laboratory Manager att Arterion's academic research partner BBV.

2008

Oct
21
Arterion was awarded second prize in the national innovation competion SKAPA.
May
15
Arterion moves to Biotech Center at Arvid Wallgrens Backe 20.
Mar
12
Arterion was mentioned as one of Sweden's 33 most interesting startups in the papers Affärsvärlden and Ny Teknik.

2007

Nov
29
Arterion was awarded 300 000 SEK from the Swedish Govermental Agency for Innovation Systems, Vinnova. The prize is awarded as part of the VinnNu programme to fule the most promising innovations of Sweden.
Sep
13
An article about Arterion was published in GöteborgsPosten.
Jan
24
The innovators behind the Arterion technology has been the focus of an article published in NyTeknik nr 3.
Jan
24
The research team behind Arterion's technology has been awarded 10 million SEK in govermental funding for research in the field of artificial vessels made of cellulose.
Jan
17
Arterion moves to new facilities at Sahlgrenska Science Park.

2006

Dec
16
Arterion has been choosen as the "Best business potential 2006 at Chalmers School of Entrepreneurship and GIBBS"
Dec
16
Full paged story about Arterion in Biotech Sweden nr 11.
May
30
Arterion was given 3rd prize in Venture Cup 2006.
Arterion develops biomaterials based on microbially derived cellulose.
Henrik Elofsson, Research Manager
Karl Richard Nilsson, CEO
Kristoffer Drotz, Production Manager
Arterion is an Encubator Portfolio Company from GIBBS class of 2006.
Arterion develops biomaterials based on microbially derived cellulose.
Medtech
Paul Gatenholm
Bo Risberg
Aase Bodin
Henrik Bäckdahl
http://www.arterion.se
+46 31-44 80 02
Arvid Wallgrens Backe 20, Gothenburg